Haemopoietic stem cell inhibition: potential for dose intensification.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002453:Cell Cycle / Q000187:drug effects; D054407:Chemokine CCL4; D016207:Cytokines / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006131:Growth Inhibitors / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D019402:Macrophage Inflammatory Proteins; D015846:Monokines / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy; D009842:Oligopeptides / Q000494:pharmacology; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives
D000970:Antineoplastic Agents; D054407:Chemokine CCL4; D016207:Cytokines; D006131:Growth Inhibitors; D019402:Macrophage Inflammatory Proteins; D015846:Monokines; D009842:Oligopeptides; C040758:hemoregulatory peptide 5b; D011761:Pyrrolidonecarboxylic Acid